A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 Years to 11 Years) With Obesity
Latest Information Update: 01 Mar 2025
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 24 Feb 2025 Status changed from recruiting to completed.
- 18 Oct 2024 Planned End Date changed from 1 Dec 2024 to 1 Jan 2025.
- 18 Oct 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Jan 2025.